Calix builds growth on BEAD-funded fiber, Gen3 shift and agentic AI, with strong backlog visibility but timing and margin noise still in focus.

As Asia’s population ages and healthcare demands rise, femtech is emerging as a mainstream growth opportunity Read more at The Business Times.

Study affirms superiority of iMDx GraftAssure assay’s proprietary dd-cfDNA combination model score: Nashville, Tennessee Monday, March 16, 2026, 18:00 Hrs [IST] Insight Molecula ...

The investigators found that dd-cfDNA levels increased with histological evidence of graft inflammation, with the strongest associations observed in microvascular inflammation (MVI) and ...

UBS Global Consumer and Retail Conference March 11, 2026 1:00 PM EDTCompany ParticipantsHarmit Singh - Executive VP ...

Q4 FY2025 earnings call recap: 9% sales growth, 5% comps, multi-price expansion, margin outlook and 2026 guidance—read key takeaways now.

Irvine-based Tarsus Pharmaceuticals posted blockbuster Q4 and full year revenues driven by surging demand for its eyedrop ...

New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary "Combination Model" score outperformed percentage-only measures of dd-cfDNARei ...

HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at Mount Sinai.

Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk ・Combines Mount Sinai’s world-class AI and ...

Kostman noted, "The 2025 trimming of our supply and demand sources to ensure higher quality will impact our year-over-year comparisons early on," with soft year-over-year performance expected through ...

Announced a 50-megawatt, 500-engine deal described as its largest yet in the segment. Gross margin -- Achieved a 17% positive gross margin in fiscal Q4 ended Dec. 31, 2025, 30 percentage points higher ...